Abstract:Objective::SOX4, a transcription factor, has been found to contribute to tumorigenesis in several cancers. This study was performed to determine whether SOX4 mediates BRAF inhibitor resistance in melanoma.Methods::Melanoma cell lines with acquired resistance to BRAF inhibitor (SK-MEL-5R, SK-MEL-28R, and A375R) were generated by adding escalating concentrations of PLX4032 into parental SK-MEL-5, SK-MEL-28, and A375 cells for >6 months. The expression of SOX4 and insulin-like growth factor 1 receptor (IGF-1R) was measured by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting. The downstream signaling of IGF-1R was detected by Western blotting. SOX4 and IGF-1R overexpression or knockdown was conducted by lentivirus transfection. Cell viability and apoptosis were demonstrated by MTT and flow cytometry, respectively. The binding ability of SOX4 to IGF-1R promoter was determined by chromatin immunoprecipitation quantitative PCR assay.Results::SOX4 was upregulated in BRAF inhibitor-resistant melanoma cells as compared with parental cells (SK-MEL-5 group, 1.02 vs. 6.33; SK-MEL-28 group, 1.03 vs. 3.22; A375 group, 1.00 vs. 1.86; t=°7.069, 29.26, and 5.291, respectively; all P < 0.01), and PLX4032 treatment could not alter the expression of SOX4 in resistant cells. SOX4 overexpression attenuated the response of parental cells to PLX4032 (for cell viability, SK-MEL-5 group: 77.76% vs. 104.28%, F= 91.50; SK-MEL-28 group: 60.59% vs. 93.13%, F= 171.8; A375 group: 62.50% vs. 80.87%, F= 47.15. For apoptosis rates, SK-MEL-5 group: 34.90% vs. 14.31%, F= 4.781; SK-MEL-28 group, 40.8% vs. 29.4%, F= 13.32, P= 0.063; A375 group: 40.20% vs. 17.09%, F= 11.39; all P < 0.05, otherwise indicated). While SOX4 knockdown enhanced the response of resistant cells to PLX4032 (for cell viability, SK-MEL-5R group: 93.75% vs. 69.53%, F= 94.45, SK-MEL-28R group: 95.60% vs. 66.79%, F= 30.41, A375R group: 95.51% vs. 59.98%, F= 111.6; for apoptosis rates, SK-MEL-5R group: 16.2% vs. 44.4%, F= 25.67, SK-MEL-28R group: 26.59% vs. 44.20%, F= 158.0, A375R group: 5.98% vs. 31.51 %, F= 14.35, and all P < 0.01). Chromatin immunoprecipitation quantitative PCR assay demonstrated that SOX4 binded to the promoter of IGF-1R (1.04 vs. 1.94 [-1044 to -920 bp] and 0.110 vs. 0.139 [GAPDH], F= 534.5, P < 0.01). In addition, SOX4 overexpression increased IGF-1R and its downstream phosphorylated ERK, phosphorylated AKT, and phosphorylated STAT3 expression, while SOX4 knockdown exerted the opposite effects. Moreover, IGF-1R knockdown overcame SOX4 overexpression-induced PLX4032 resistance (cell viability: 35.85% vs. 52.79% vs. 37.84% [A375 group, negative control group vs. SOX4 overexpressing group vs. SOX4 overexpressing + sh-IGF-1R group]; apoptosis rates: 25.30% vs. 9.56% vs. 22.26 [A375 group, negative control group vs. SOX4 overexpressing group vs. SOX4 overexpressing+ sh-IGF-1R group]; F= 13.01 and 41.87, respectively; all P < 0.01), while IGF-1R overexpression abrogated SOX4 knockdown-induced response enhancement to PLX4032 for comparison of negative control group, sh-SOX4 group and sh-SOX4 + IGF-1R overexpressing group (cell viability: 96.62% vs. 86.86% vs. 97.26% (A375R), 98.15% vs. 81.63% vs. 98.49% [SK-MEL-5R]; apoptosis rates: 13.81% vs. 32.00% vs. 12.16 [A375R], 29.70% vs. 41.40% vs. 26.10% [SK-MEL-5R]; F= 13.56, 12.86, 38.81, and 39.85, respectively; all P < 0.01). Conclusion::SOX4 mediates BRAF inhibitor resistance in melanoma through regulation of IGF-1R signaling. SOX4 might serve as a potential target for the treatment of BRAF inhibitor-resistant melanoma.

Icariside II Overcomes BRAF Inhibitor Resistance in Melanoma by Inducing ROS Production and Inhibiting MITF

Icariside II Induces Apoptosis of Melanoma Cells Through the Downregulation of Survival Pathways.

Icariside II inhibits cell proliferation and induces cell cycle arrest through the ROS-p38-p53 signaling pathway in A375 human melanoma cells.

Icariside II Potentiates the Anti-Pd-1 Antitumor Effect by Reducing Chemotactic Infiltration of Myeloid-Derived Suppressor Cells into the Tumor Microenvironment Via ROS-mediated Inactivation of the SRC/ERK/STAT3 Signaling Pathways.

Icariside Ii Potentiates Paclitaxel-Induced Apoptosis In Human Melanoma A375 Cells By Inhibiting Tlr4 Signaling Pathway

Mir‐200c/bmi1 Axis and Epithelial–mesenchymal Transition Contribute to Acquired Resistance to BRAF Inhibitor Treatment

E2F1/IGF-R Loop Contributes to BRAF Inhibitor Resistance in Melanoma

Icariside II induces apoptosis via inhibition of the EGFR pathways in A431 human epidermoid carcinoma cells.

Icariside II enhances cisplatin-induced apoptosis by promoting endoplasmic reticulum stress signalling in non-small cell lung cancer cells.

Sestrin2 Contributes to BRAF Inhibitor Resistance Via Reducing Redox Vulnerability of Melanoma Cells

Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling

Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment

Isoliquiritigenin suppresses the progression of malignant melanoma via targeting H2A.Z.1-E2F1 pathway

Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines

PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism

SOX4 Mediates BRAF Inhibitor Resistance in Melanoma through Regulation of IGF-1R Signaling: In Vitro Study

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma

Microbiome analysis combined with targeted metabolomics reveal immunological anti-tumor activity of icariside I in a melanoma mouse model

SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA

Abstract 5869: Investigation of molecular alterations associated with double resistance to BRAF and MEK inhibition in melanoma